Product name

Apoptosis-Inducing Metal-Containing-Nucleoside-Analogues

Summary

The efficiency of inducing apoptosis by nucleoside analogues is significantly increased when a metal complex is added to the new chemical entities by Nucleoside analogues.

Organization name

IPAL GmbH

Profile

Advantages

• Strong apoptosis-inducing properties
• The metal-containing nucleoside analogues (MEcNA) are structurally novel
• The compounds are different from previously known nucleoside analogues used for therapy (e.g. cytarabine and fludarabine -5´ dihydrogenphosphate)
• Induce apopototic cell death not only in permanent cell lines produced from tumors (e.g. BJAB, MCF7, NCI-H460, HCT 116, DU 145, MaTu, MaTu- ADR cells), but also in primary cells of patients suffering from acute leukemia (CML, AML, ALL and ALL-Rez, IC50 in the range of 2-10μM)
• MEcNA-induced apoptosis is CD95/Fas and Caspase-3 independent
• Capable of breaking existing resistances towards cytostatic agents
• Due to the pronounced lipophilicity of the substances trespassing of the blood-brain barrier is possible. Therefore, MEcNA´s may also be employed for malignant brain tumors

Patents have been granted in several European countries. Patent applications are filed in the US and Japan.

The technology was developed at Charité-Universitary Medicine Berlin and is offered by IPAL.

ipal GmbH
Dr. Andreas Voigt
andreas.voigt(at)ipal.de

About IPAL

The ipal GmbH patent agency assesses and markets the inventions of scientists in the area of Life Sciences and Physics & Engineering from Charité-Universitätsmedizin (University Medicine), Robert Koch Institute, Deutsches Herzzentrum (German Heart Institute), Bundesanstalt für Materialprüfung (BAM - Federal Institute for Materials Research and Testing), the Zuse Institute as well as the Paul Ehrlich Institute, Langen and the Jacobs University Bremen. IPAL provides all of the services necessary - from the assessment of patentable technologies to a comprehensive patent protection all the way to the evaluation of sales returns potentials on the market and successful commercialisation through the use of licensing agreements.

Description File

 02133_NucleosideAnalogues_TA.pdf

URL

http://www.ipal.de/en/technology_offers/life_sciences/

Your feedback

back

Search

Sector

--- select from list ---AgroBiotechnologyBiomedicine, DiagnosticsCosmeticsEnabling Technology, Platform TechnologyEnvironmentalFine ChemicalsFoodMedical DeviceProduction, Development ServicesVeterinary

Technology

--- select from list ---AnalyticalAnimal ModelAntibody BasedAntisense, NucleotideBioinformaticBiologicalBlood Products, SubstitutesBreeding, CultivationChemistryClinical Research ServicesCompound LibrariesDiagnostic Assay, KitDrug DeliveryDrug DiscoveryDrugs, Small MoleculeEngineeringEnzymesGene Therapy, VectorsGenomicsHigh Throughput ScreeningImagingImplantIndustrial Waste Treatment, RemediationNanotechnologyNatural ProductsPeptides, ProteinsPharmacogenomicsPreclinical Research ServiceProteomicsReagents, Media RegenerationRenewable resourcesSurgical InstrumentationTissue Engineering, BiomaterialTransgenic OrganismTransplantVaccines

Development Stage

--- select from list ---Clinical Phase IClinical Phase IIClinical Phase IIIClinical Phase IV/MarketedIdea, Conceptin-vitro TestingLead Compound/SeriesPreclinicalProof-of-principlePrototypeRepurposingTarget Identification, Validation, Drug Discovery

Disease Category

--- select from list ---(Auto) ImmuneCancerous, neoplasmaticInfectious, ParasiticInflammatoryInherited, NeonatalMetabolic, EndocrineOther, organ-specific diseases

Organ

--- select from list ---BloodBoneBrainBreastCardiovascularCartilageCNS, Nerves, SpineEarEsophagusEyeGynecologyHeartImmune SystemIntestineLiverMusclePancreasPNSProstate and male sexual healthPsychiatry, psychologyRespiratorySkinTeethUrology, kidney